News Hub | News Direct

All Industries


Article thumbnail News Release

Texas’ Leading Hormone Provider Expands Cutting-Edge Preventative Screening Tool to All Clinics

Forum Health

Hormones by Design, a Forum Health provider and leader in hormone replacement therapy, has acquired DITI Imaging – a pioneer in digital infrared thermal imaging. This strategic move combines the expertise of both companies to offer comprehensive and preventative health care to two of its five renown Texas locations. Learn more about Hormones by Design. Digital infrared thermal imaging (DITI) is a non-invasive, radiation-free screening tool to detect early signs of inflammation and abnormal blood flow patterns, which may be precursors to various health conditions. By identifying these indicators early, patients can proactively address potential issues before they develop into more serious conditions. Phil Hagerman, Forum Health CEO: “ With 1 in 8 women diagnosed with breast cancer and chronic inflammatory diseases on the rise, early detection is paramount. This acquisition underscores our commitment to advancing personalized, integrative healthcare and providing the latest, top-of-the-line technology to help our patients achieve optimal health.” DITI is the only screening tool capable of detecting inflammation and associated heat patterns unlike X-rays, mammograms, MRIs and ultrasound tests. Some of the many health conditions DITI can screen for are: Breast cancer Early indications of asymptomatic and systemic inflammatory and degenerative processes Systemic, artery, dental, and sinus inflammation Unexplained and referred pain, including arthritis and nerve damage Fibromyalgia and digestive disorders Overactive and underactive thyroid conditions Dr. Melissa Miskell, Hormones by Design founder: "We’re thrilled to welcome DITI Imaging into the Hormones by Design family. It allows us to expand our preventative healthcare offerings, better monitor the effects of hormone therapy, more comprehensively treat patients with thyroid conditions, and help people maintain optimal health as they age.” Patients will have access to advanced screening services, including breast, full-body, and region-specific imaging, in addition to personalized BHRT options. Schedule an appointment or find a Hormones by Design location near you. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

May 09, 2024 08:50 AM Eastern Daylight Time

Article thumbnail News Release

6.7 Million Americans Live With Alzheimer’s – IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings

IGC Pharma, Inc. (IGC)

By Faith Ashmore, Benzinga Over 6.7 million Americans aged 65 and older are living with Alzheimer’s disease (AD) and this number is predicted to grow to 13.8 million by 2060. AD is the sixth leading cause of death in the U.S. and in 2023, it was projected to cost the U.S. $345 billion. Alzheimer's disease is characterized by a gradual decline in memory, thinking, behavior and social skills; however, a lesser-known subsection of Alzheimer’s patients – despite a prevalence of 40%-80% in the patient population – suffer from Agitation in Alzheimer’s Disease (AAD). AAD is associated with higher admission rates to assisted living facilities, higher use of medications, higher rates of long-term hospitalizations and higher mortality rates for Alzheimer’s patients. This brings a significant emotional and financial cost to patients and caregivers. Currently, there is no perfect treatment for AD or ADD. Otsuka’s (OTC: OSUKF) Rexulti is one of the major medications currently being explored as a potential treatment for Alzheimer's disease. It was originally developed as an atypical antipsychotic to help treat mental health illnesses, and it is believed to work by affecting the activity of certain neurotransmitters in the brain. Due to this, ongoing research is investigating its potential to address the behavioral and psychological symptoms often associated with the condition, such as agitation and aggression, but some concerns are yet to be addressed. One of the major criticisms of Rexulti is that it carries a black box warning regarding the increased risk of death in elderly patients with dementia-related psychosis. Patients have reported adverse events associated with the drug like restlessness, weight gain and sleepiness. IGC Pharma (AMEX: IGC) is looking to an alternative to existing drugs with its drug, IGC-AD1, which has been specifically designed to target the underlying causes of AAD and aims to fill the gap for a safe and effective therapy. IGC Pharma began developing IGC-AD1 in 2017, and it was approved by the FDA as an investigational new drug in 2019. IGC-AD1 is designed to target neuroinflammation and dysfunction of the CB1 receptor. This investigational drug contains THC as one of two active pharmaceutical agents. THC is the primary psychoactive compound found in the cannabis plant. IGC-AD1 is undergoing extensive clinical trials to evaluate its effectiveness and safety in treating Alzheimer's disease. After a successful phase 1 clinical trial that resulted in patent protection in the U.S., the company has moved on to phase 2 trials. The phase 2 clinical trial, begun in 2023, encompasses 20 sites across the United States and Canada. With a target of 146 participants, this trial focuses on determining the efficacy of IGC-AD1 in alleviating agitation in Alzheimer's patients. The company has just announced the results of an interim analysis of its ongoing phase 2 trial. The main objective of the study is to evaluate the change in AAD over six weeks, utilizing the Cohen Mansfield Agitation Inventory (CMAI). According to IGC Pharma, the study showed that patients who were given IGC-AD1 had a more significant reduction in agitation levels compared to those who were given a placebo, with positive effects being observed as early as week two of the trial. At the six-week mark, the difference in agitation levels between the IGC-AD1 group and the placebo group was quite noticeable, with an effect size of 0.66 according to Cohen's d measure. The mean difference in the CMAI scores between the active treatment and placebo was -10.45, which indicates a meaningful contrast. Additionally, at the two-week mark, a secondary evaluation showed a positive effect size of 0.79 for IGC-AD1 compared to the placebo. If IGC-AD1 continues to perform well in clinical trials, it could be an effective, simpler and faster treatment option for patients – and importantly, the company is aiming to deliver a product with full approval from the FDA without major black box warnings. The formula as an oral liquid solution also caters to the older population. For millions of Americans who have family members with AD or are worried about developing AD later in life, this drug could provide hope. Featured photo by Cristina Gottardi on Unsplash. IGC Pharma Inc. (IGC) is at the forefront of the fight against Alzheimer's disease, developing innovative solutions to address this devastating illness. The company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2b clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma is actively leveraging Artificial Intelligence (AI) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Rosalyn Christian rchristian@imsinvestorrelations.com Company Website https://igcpharma.com/

May 09, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

ASSOCIATION OF PICKLEBALL PLAYERS ANNOUNCES HISTORIC SPONSORSHIP WITH THE JAMES AT OHIO STATE

AOPP

The Association of Pickleball Players (APP) announced today a landmark sponsorship with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), one of the nation’s leading cancer research and treatment centers. The OSUCCC – James is now the presenting sponsor of the inaugural APP Women’s Open, which will take place Oct. 4-6, 2024, at Pickle & Chill in Columbus, Ohio and broadcast nationally, to kick off National Breast Cancer Awareness Month. Evident in its name, this APP Signature Event will be a global platform for female competitors at all levels. The professional and amateur tournament will offer $75,000 in prize money and feature women competing in doubles and singles, including skinny singles for women 50 and over. The event will also feature social programming and entertainment designed to celebrate and fuel the growth of pickleball for women, ultimately creating a healthier and more active community. All key elements of the vibrant, multi-day event will be presented by women—from players and referees to administrators and broadcasters. “I am thrilled to stand alongside The James to elevate and celebrate women in pickleball and support Breast Cancer Awareness Month,” said Shannon Dan, APP EVP of global partnerships. “The APP Women’s Open presented by The James will be part tournament, part festival and 100% fun for women of all ages and skill levels. It’s an event designed by and for women: a place to compete, celebrate and connect.” The OSUCCC – James is a world-class cancer treatment and research institution. It has been a designated National Cancer Institute Comprehensive Cancer Center since 1976 and has been one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years. It also has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation. In addition to the presenting sponsorship of the APP Women’s Open, The James has been named the official and exclusive hospital of the upcoming 2024 APP Vlasic Classic in Cincinnati on May 7-12, and for the APP Tour beginning in 2025. Pickle & Chill in Columbus, Ohio, the largest dedicated indoor/outdoor pickleball facility in the Midwest, will host the first-of-its kind pickleball event. Founded in November 2022, Pickle & Chill features 19 total courts, a 30,000-square-foot event plaza, and an indoor bar and mezzanine space. Additional information on registration, tickets and more will be available at theapp.global. # # # About The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities. The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. As the cancer program’s adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation. The Association of Pickleball Players (APP) provides opportunities for pickleball players of all ages and skill levels—professionals, amateurs and recreational—to compete in world-class pickleball events for the opportunity to win prize money and be seen on more than 40 hours of nationally televised pickleball action on CBS Sports, ESPN and FOX Sports. Since its launch in 2019, the APP has operated the first and only pro and amateur pickleball tour fully and officially sanctioned by USA Pickleball and became the first pickleball organization ever to establish an official headquarters and training center with The Fort in Fort Lauderdale, Fla. The APP Tour’s 2024 schedule features the most robust pickleball showcase across pro and amateur competitions, with 20 events across the country offering various combinations of single, doubles and mixed doubles play as well as pro team competitions. The APP prides itself on growing the game and developing the next generation of pickleball champions through its nationwide network of APP UTR Sports Pickleball Leagues and the Doubles Dink for Cancer fundraising program benefitting the American Cancer Society; support of international pickleball events and the APP’s Atlantic Cup, featuring Team USA vs. Team Europe; and youth initiatives including the APP Junior Circuit, APP Next Gen Series and APP Next Gen U.S. National Team. The 2024 tournament schedule, recent news and additional information about the APP are available at theapp.global and on Instagram, X, Threads, TikTok, Facebook and LinkedIn. Contact Details Daniel Sagerman +1 847-800-8182 dsagerman@theapp.global Company Website https://theapp.global

May 09, 2024 08:30 AM Eastern Daylight Time

Article thumbnail News Release

Generation Shift: Why Millennials and Gen Z Might Ditch Old-School Investment Firms

MarketJar

Traditional wealth management companies might need to rethink their strategy or risk losing younger clients with new regulations set to reveal high banking fees. According to a new investment satisfaction survey by J.D. Power, 25% of Gen Z and 22% of Millennials would consider switching wealth management firms in the next year, citing high transaction costs as their main concern. 1 The upcoming fee transparency regulations, known as total cost reporting, are set to take effect in 2026 and would require more clarity and communication in explaining the costs and fees associated with investments. This sentiment is echoed in findings from a Broadridge/Roubini ThoughtLab survey, which illustrates that Millennials possess a deep understanding of financial concepts critical to investment success. They are acutely aware of how fees can eat into returns, prefer index funds for their cost-effectiveness, and understand the use of derivatives for risk mitigation. These evolving preferences indicate a seismic shift in how younger generations approach investing, prioritizing transparency, low fees, and the ethical dimensions of their investment choices. This shift provides a fertile ground for innovative financial technology companies like Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO), which is stepping in to meet these new consumer demands with modern, user-friendly solutions. Mogo Redefines Finance with Millennial-Centric Solutions Mogo, which is one of Canada's largest FinTech companies, stands out with its innovative approach to simplifying finance and empowering users to take control of their financial futures. With services like MogoTrade and Moka.ai, Mogo offers Millennials and Gen Zers a compelling alternative to traditional money managers, aligning with their desire for transparency, low fees, and accessible wealth-building opportunities. Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) boasts over 2 million members and processes $9.9 billion in payments annually. Mogo also holds around 13% equity in WonderFi, which operates Canada’s only fully regulated crypto exchange. The Mogotrade platform allows users to trade stocks without commission, following a long-term investing strategy inspired by Warren Buffett, while its recently launched Moka.ai, a revamped version of its wealth-building application, which leverages behavioral science principles and provides tools for setting and managing financial objectives to guide users towards financial success. Moka.ai charges a $7 monthly fee, regardless of investment size, contrasting traditional high-fee mutual funds. Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) recently announced its Q4 and FY 2023 financial results, marking significant strides in operational efficiency and profitability. Under the leadership of founder and CEO David Feller, the company focused on enhancing its digital wealth platform, culminating in the successful relaunch of Moka and Mogo. These efforts contributed to a slight increase in Q4 revenue to $17.2 million and a gross profit of $11.5 million. Operational efficiencies reduced total operating expenses by 25% to $11.7 million for the quarter, boosting revenue per employee by 83% since Q1 2022. The year also ended on a high note with net income of $8.5 million, a dramatic improvement over the previous year's net loss of $74.9 million. Mogo 's commitment to innovation is further underscored by its new strategy to include Bitcoin and Bitcoin ETFs in its treasury management, reflecting its adaptability and forward-thinking approach in the financial sector. Mogo ’s investment portfolio includes several crypto-related ventures that represent about 35% of the company's total market cap value. This includes investments into Canada’s leading digital currency exchange WonderFi, American digital currency exchange Gemini Trust, and Canada’s first licensed digital asset custodian, Tetra Trust. This exposure positions Mogo to benefit from the growing digital currency sector, which is expected to reach $11.71 billion by 2030. 2 Click on this link to learn more about Mogo Inc. (TSX:MOGO)(NASDAQ:MOGO). Footnotes: [1] https://ca.finance.yahoo.com/news/young-investors-more-likely-switch-100000539.html [2] https://www.grandviewresearch.com/industry-analysis/cryptocurrency-market-report Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mogo Inc.. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Mogo Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Mogo Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-mogo. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mogo Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mogo Inc.’s industry; (b) market opportunity; (c) Mogo Inc.’s business plans and strategies; (d) services that Mogo Inc. intends to offer; (e) Mogo Inc.’s milestone projections and targets; (f) Mogo Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Mogo Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mogo Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mogo Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mogo Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mogo Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Mogo Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mogo Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mogo Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mogo Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mogo Inc.’s business operations (e) Mogo Inc. may be unable to implement its growth strategy; and (f) increased competition.Except as required by law, Mogo Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mogo Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mogo Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mogo Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mogo Inc. or such entities and are not necessarily indicative of future performance of Mogo Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 09, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Real Advantage: Prop-Firm Offering Real Brokerage Accounts

Benzinga

By Austin DeNoce, Benzinga The trading landscape is characterized by an incredibly diverse marketplace. Proprietary trading firms (prop firms) are just one of its many innovations that have provided a pivotal path for ambitious traders seeking to leverage extensive capital, advanced tools and the wisdom of seasoned professionals. However, the journey from a novice to a seasoned trader involves a crucial choice between trading in a simulation account (SIM) and stepping into the real arena with a real brokerage account through a prop-firm. This decision can significantly impact a trader's development, strategy execution and psychological readiness for the market's challenges. Trading Real Money With Real Brokerage Accounts Through Prop Firms Trading through a real brokerage account unlocks a thrilling world where precision, real-time decision-making and genuine market forces all intersect. Here, every trade has tangible consequences reflected in your very real money. Profits earned are profits received and paper losses aren’t so fictional anymore. This prospect is exciting to some and terrifying to others, but if you’re a serious trader, this is the only path forward. So it is important to bear in mind the advantages of trading through a real account: Direct market engagement: Real accounts provide a more accurate and reliable data feed, which is essential for making informed decisions and practicing real-time decision-making. Quick payouts: Successful trades can generally be liquidated as soon as the next day, enabling a straightforward cashout process to enjoy your profits. Unrestricted trading styles: Real accounts typically offer fewer restrictions on trading strategies, allowing for a broader range of tactics, from high-frequency trading to long-term positions. Regulatory clarity: Every transaction is recorded and traders receive comprehensive reports that provide useful data and clarity as well as trust in the trading process. Technological edge: Real accounts leverage superior computing resources and bandwidth to ensure high performance and reliability throughout your trading. The Limitations Of SIM Account-Only Prop Firms While SIM accounts serve as valuable training grounds, they come with notable drawbacks that can hinder a trader's growth and realistic understanding of market dynamics. For instance, consistency rules can limit the potential for large trades since prop firms often have to pay out of their own pocket for SIM accounts, and some prop firms also encourage users to open multiple accounts – resulting in higher costs for the trader. Below are some other considerations to keep in mind when not using a real brokerage account: Withdrawals of profit: Here you will meet a lot of rules you must follow in order to get a payout. You have to be trading a certain number of days and can only request payout on specific dates. Then there are rules about consistency and limits to the amount you can take out. Prop firms can deny you payouts because you traded through news or earnings. There are a lot of different rules just to make it harder for you to get your hard earned money. Artificial trading environment: SIM accounts often operate under a set of restrictive rules that may not accurately reflect real market conditions, limiting the potential for practical development and experience. Delayed execution: The computing and bandwidth resources allocated to SIM accounts are typically inferior to those of live servers, potentially affecting trade execution. This, again, can distance you from the real experience and skills you need to succeed as a trader. Psychological dissonance: The lack of real financial risk can lead to complacency, impacting a trader's ability to handle real market pressures related to fear and greed. No matter how prepared you think you are, introducing real money changes everything, and you need to be prepared to handle that. BluSky: Paving a Path To Real Market Success BluSky Trading Company is a leading proprietary trading firm for traders seeking to make a seamless transition from the simulated world to the tangible pressures and opportunities of real market trading. With a focus on fostering trader development, BluSky offers a compelling package for those ready to embrace the challenges and rewards of real brokerage accounts: Payout rules: These are simple; what is your balance and how much buffer do you need to keep trading. No limiting rules. Simplified transition: Passing BluSky's evaluation with a maximum of 25% consistency allows traders to reclaim their first month's subscription fee; a unique incentive to commit to real trading. Enhanced trading capacity: Once in a brokerage account, traders have the opportunity to expand their trading arsenal with more contracts, bypassing the need for further evaluations. Personalized coaching: BluSky also stands out by offering one-on-one coaching for brokerage account holders, ensuring traders have the support and guidance to refine their strategies and mindset. Free live trade room: You benefit from the expertise of a professional trader who invests their own money. Engage freely, ask questions, and participate in special educational events at no additional cost. Beyond the bell: Follow BluSky’s post-market YouTube show, where you can continue learning from a seasoned trader and coach. Real Success Requires Real Trading Choosing to work with a prop firm using real brokerage accounts is crucial for any trader focused on professional advancement and financial achievement. The advantages of real trading - such as enhanced data feeds, regulatory clarity, and supporting educational initiatives - far surpass any involvement of prop firms using simulated environments. Prop firms like BluSky aim to provide a well-defined route to authentic trading experiences, supported by top-notch technology and exceptional guidance. This makes the journey into professional trading more accessible than ever. For those ready to tackle the challenges and seize the opportunities of a real brokerage account, this transition not only fosters professional growth, but also unlocks the vast potential of the financial markets. Featured photo by Chris Liverani on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

May 09, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Artemis Resources says Mt Marie prospect is fast becoming a 'priority one target' for lithium

Artemis Resources Ltd

Artemis Resources Ltd (ASX:ARV, AIM:ARV, OTCQB:ARTTF) executive director George Ventouras highlights promising results from latest sample assays from the Mt Marie lithium prospect in the Pilbara region of Western Australia. Ventouras expressed excitement over recent high-grade findings at Mt Marie, describing it as a priority target due to consistent high-grade assay results. He also noted encouraging results from Osborn East, showing consistency with yields above half a percent, though not as high as Mt Marie, but demonstrating potential in terms of strike length. The next steps for Artemis include awaiting heritage clearances for Mt Marie, with drilling expected to commence early in the new financial year around July or August. Ventouras detailed plans for extensive ground reconnaissance and sampling to further understand the lithium mineralisation and prepare for the drilling phase. Additionally, Artemis announced a fundraising initiative, the proceeds of which will support the lithium exploration and development of its gold prospects, with Lulu Creek also highlighted as a priority. The focus is on advancing these projects and enhancing the understanding of the geology to optimise exploration efforts. Contact Details Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

May 09, 2024 07:46 AM Eastern Daylight Time

Video
Article thumbnail News Release

First Tin advances strategic tin projects in Australia and Germany to fill supply deficit

First Tin PLC

First Tin PLC CEO Bill Scotting joins Proactive's Stephen Gunnion with details of the two tin mining projects the company is developing in Australia and Germany. Scotting said the Taronga project, near Brisbane, will operate as an open pit mine and is expected to produce approximately 3,500 tonnes of tin concentrate annually. The German project, Tellerhäuser is being developed as an underground mine and will target multiple metals, including tin, indium, copper, and zinc. Both projects are situated in historic tin mining districts, with the German site dating back centuries. Scotting said technological advancements in mining and processing have enabled more efficient extraction and processing of tin. Market dynamics, such as increased tin pricing, have also improved the economic viability of these projects. Additionally, he noted that First Tin implements high environmental standards in its operations, including the use of solar power in Australia and adherence to strict environmental regulations in both countries. Scotting highlighted the growing global demand for tin, driven by its critical role in electronic manufacturing and the energy transition, including solar energy and electric vehicles. He noted a structural change in the market, with increasing tin usage in various high-tech applications. He also pointed out the strategic advantage of their mines' locations in OECD countries, which ensures a more stable and secure supply chain compared to tin sources in emerging economies. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

May 09, 2024 07:41 AM Eastern Daylight Time

Video
Article thumbnail News Release

Eden Research reports strong growth and new product introductions in 2023

Eden Research PLC

Eden Research PLC CEO Sean Smith tells Proactive's Stephen Gunnion the company achieved significant advancements and a robust performance in 2023. Revenue for the year to 31 December 2023 increased by 78% to £3.2 million, surpassing market expectations. This growth was attributed to strong sales across various product lines. A noteworthy development was a successful fundraising event that raised £9.9 million, enhancing the firm's cash position and enabling further product development. In partnership with Corteva Agriscience, Eden introduced Ecovelex, a new seed treatment product designed to repel birds from maize, marking a new category for the company. This product received temporary approval in Italy, facilitating its use in the 2024 growing season. Additionally, Eden expanded its product range to include an insecticide targeting pests like mites and aphids, which has undergone extensive field testing with over 140 trials worldwide. Regulatory approvals for Mevalone were a significant focus, with expansions in the US including crucial approval in California, important for the grapevine fungicide market. Looking forward, Smith said the company is optimistic about 2024, despite potential challenges from climate conditions and regulatory dependencies. Key future developments include ongoing product label expansions and regulatory authorisations, particularly in Europe. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 09, 2024 07:39 AM Eastern Daylight Time

Video
Article thumbnail News Release

Genflow Biosciences advances three major programs in fight against ageing diseases

Genflow Biosciences PLC

Genflow Biosciences PLC CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline. Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing. The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location. In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 09, 2024 07:37 AM Eastern Daylight Time

Video
1 ... 208209210211212 ... 3754